Johnson & Johnson will soon start testing its COVID-19 vaccine candidate in U.S. adolescents, the company announced Friday. The company plans to begin testing the vaccine in a small number of 16 and 17 year olds as part of an ongoing Phase 2 trial for adults, gradually expanding the trial to children aged 12-17 after reviewing the initial data.

It is currently enrolling adolescents in Spain and the United Kingdom and expects to start enrolling them soon in the U.S., Netherlands and Canada, followed by Brazil and Argentina.

In February, the U.S. Food and Drug Administration authorized emergency use of the vaccine for individuals 18 and older. 

Related News Articles

Headline
The New Hampshire Hospital Association and the Foundation for Healthy Communities Sept. 29 received a Power of Associations Gold Award for their efforts during…
Perspective
With fall in full swing, there are two easy steps that individuals can take to protect themselves and their families against illness — get a flu shot and get a…
Headline
In a study of 151 tax-exempt hospitals reported yesterday in JAMA Network Open, 84% updated their charity care policies between 2019 and 2021. Among the…
Headline
Pfizer has submitted a request for the Food and Drug Administration to authorize a 10-microgram booster dose of its bivalent COVID-19 vaccine booster for…
Headline
Health care providers who treat uninsured or underinsured patients with commercially procured bebtelovimab, a COVID-19 monoclonal antibody therapy for…
Headline
The Centers for Medicare & Medicaid Services Friday reopened the comment period for a 2020 interim final rule that set forth certain requirements for…